Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DVC36K
|
|||
| Drug Name |
GNSC-001
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Osteoarthritis [ICD-11: FA00-FA05; ICD-9: 715] | Phase 1 | [1] | |
| Company |
Genascence
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-1 receptor antagonist protein (IL1RN) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05835895) A Phase 1b, Randomized, Double-Blinded, Placebo-Controlled Dose Ranging Study to Evaluate Safety, Tolerability and Pharmacodynamics of a Single Intra-articular Injection of GNSC-001 Gene Therapy in Subjects With Osteoarthritis of the Knee. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Genascence | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.